Table 4 Registered clinical trials involving targeting TAMs in gynecological and breast cancers
TAM target | NCT Number | Study results | Conditions | Interventions | Phases | Year of registration |
|---|---|---|---|---|---|---|
CAR-M | NCT04660929 | NA | Breast cancer Ovarian epithelial cancer | Biological: CT-0508 | Phase 1 | 2020 |
CD47 | NCT04881045 | NA | Ovarian cancer | Biological: PF-07257876 | Phase 1 | 2021 |
| Â | NCT03957096 | NA | Breast cancer Ovarian cancer | Drug: SGN-CD47M | Phase 1 | 2019 |
|  | NCT02890368 | NA | Breast cancer HPV-related malignant neoplasm | Drug: TTI-621 monotherapy Drug: TTI-621 + PD-1/PD-L1 Inhibitor Drug: TTI-621 + pegylated interferon-α2a Other: TTI-621 + T-Vec Other: TTI-621 + radiation | Phase 1 | 2016 |
| Â | NCT02125344 | NA | Breast cancer | Drug: non-pegylated liposomal doxorubicin Drug: Carboplatin Drug: Paclitaxel Drug: Epirubicin Drug: Cyclophosphamide Drug: Pertuzumab Drug: Trastuzumab Drug: Ferric carboxymaltose | Phase 3 | 2014 |
TLR | NCT04278144 | NA | HER2-positive solid tumors | Drug: BDC-1001 Drug: Pembrolizumab | Phase 1/2 | 2020 |
| Â | NCT04116320 | NA | Breast cancer Cervical cancer Ovarian cancer | Device: Echopulse Drug: Imiquimod Drug: Standard of care PD-1 therapy | Phase 1 | 2019 |
| Â | NCT01421017 | NA | Breast cancer Metastatic breast cancer Recurrent breast cancer | Radiation: Radiation Drug: Imiquimod Drug: Cyclophosphamide | Phase 1/2 | 2011 |
| Â | NCT00899574 | 2 patients achieved a partial response (20%; 95% CI, 3%-56%) | Breast cancer Breast neoplasms | Drug: Imiquimod | Phase 2 | 2009 |
| Â | NCT00319748 | 0 complete response, 0 partial response, 1 stable disease, 2 progressive disease | Breast cancer Ovarian cancer Endometrial cancer Cervical cancer | Drug: 852A | Phase 2 | 2006 |
CSF | NCT04542356 | NA | Cervical cancer | Drug: PEG-rhG-CSF Drug: rhG-CSF | Phase 2 | 2020 |
| Â | NCT04514692 | NA | Cervix cancer Endometrial cancer | Diagnostic Test: FDG PET/CT Drug: GCSF | Phase 1/2 | 2020 |
| Â | NCT04418219 | NA | Breast cancer | Drug: Cyclophosphamide Biological: Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM Biological: Pembrolizumab Biological: Recombinant Interferon Alpha 2b-like Protein Other: Questionnaire Administration Other: Quality of Life Assessment | Phase 1/2 | 2020 |
| Â | NCT04144023 | NA | Breast ductal carcinoma in situ | Biological: Granulocyte-macrophage colony-stimulating factor Biological: Multi-epitope HER2 peptide vaccine H2NVAC Procedure: Therapeutic conventional surgery | Phase 1 | 2019 |
| Â | NCT03858166 | NA | Ovarian neoplasms Ovarian cancer | Drug: PEG-rhG-CSF | Phase 4 | 2019 |
| Â | NCT03206684 | NA | Cervical cancer | Drug: PEG-rhG-CSF Drug: rhG-CSF | Phase 4 | 2017 |
|  | NCT02978222 | NA | Platinum-sensitive ovarian cancer Ovarian cancer | Biological: FRα peptide plus Adjuvant (GM-CSF) Drug: Adjuvant (GM-CSF) Alone | Phase 2 | 2016 |
| Â | NCT02469116 | 16 complete response, 1 partial response, 0 stable disease, 1 progressive disease | Ovarian cancer | Drug: Docetaxel Drug: Carboplatin Drug: Pegylated G-CSF | Phase 2 | 2016 |
| Â | NCT02017678 | NA | Ovarian cancer | Biological: JX-594 | Phase 2 | 2013 |
|  | NCT01570036 | DFS was improved for NeuVax versus control (HR, 0.26; 95% CI, 0.08–0.81, P = 0.01) | Breast cancer | Drug: Herceptin Drug: NeuVax vaccine Drug: GM-CSF (control) | Phase 2 | 2012 |